CAR T-Cell Therapy

During a live event, Paolo Strati, MD and participants explore when to use CAR T in relapsed LBCL, how bispecific antibodies fit, and practical scan, access, and frontline CD19 strategy shifts.

Community oncology teams partner with health systems to deliver advanced therapies safely, using hybrid dosing, toxicity backup, and local follow-up.

How community oncology prepares for CAR T and gene therapy: safety gains, tech, payer shifts, and 3 must-have capabilities to expand access.

Off-the-shelf CD19 CAR T boosts MRD clearance in first-line LBCL consolidation, with no CRS/ICANS and strong outpatient community feasibility.

Community oncology practices can deliver chimeric antigen receptor (CAR) T-cell therapy safely, effectively, and in a sustained manner.

AZD0120, a rapidly manufactured CAR T product, was used successfully in a small number of patients with multiple myeloma with older age and frailty.

FDA fully approves brexu-cel CAR‑T for relapsed mantle cell lymphoma, with ZUMA‑2 showing deep responses and key infection-care tips for clinicians.

During a live event, Paolo Strati, MD and participants explored anti‑CD19 CAR T options for relapsed LBCL—including eligibility and eased REMS rules.

Statin use alongside CD19 CAR T shows longer survival and less neurotoxicity in relapsed large B-cell lymphoma, prompting calls for trials.

FDA confirms brexu-cel CAR-T for relapsed mantle cell lymphoma, citing 91% response in BTK-naive patients and updated safety guidance.

New analysis of 2304 patients shows CD19 CAR T-cell therapy efficacy is consistent across races, with outcomes driven by tumor burden and ECOG status.

Ten-year trial shows CD22 CAR T drives deep remissions in relapsed pediatric B-ALL, with transplant boosting durability and manageable toxicity.

Real-world brexu-cel CAR-T data in adult R/R B-ALL show trial-like ICANS, CRS, and highlight monitoring and risk factors.

Phase 2 data show one-time liso-cel CAR T delivers 95% responses in hard-to-treat marginal zone lymphoma, with low severe CRS and neurotoxicity.

A single-arm study of a BCMA CAR T-cell therapy after induction for newly diagnosed multiple myeloma led to 100% minimal residual disease negativity at 3 months.

MRD testing in lymphoma grows fast, but varying assays and limited guidelines leave clinicians guessing; trials and standards clarify care.

Sagar Lonial, MD, discusses the expanding potential uses of cereblon E3 ligase modulators (CELMoDs) in combination with T-cell redirection therapies in multiple myeloma.

Real-time ctDNA MRD testing guides early chemo de-escalation in diffuse large B-cell lymphoma, aiming to cut toxicity without losing cure rates.

Logic-gated CAR T A2B543 enters EVEREST-2 arm 2, adding membrane-tethered IL-12 to boost solid-tumor potency while limiting toxicity.

Macrophage cell therapy may skip lymphodepleting chemo, reducing toxicity and secondary cancer risk for heavily pretreated, frail patients.

Preclinical and early clinical data showed that a proteasome inhibitor could increase BCMA expression after failure of CAR T-cell therapy.

RB-1355 reprograms autologous macrophages to heat up lymphoma tumors, avoid lymphodepletion, and deliver fast 1-week cellular therapy.

New Uniphar deal widens European managed-access to Lymphir for relapsed CTCL, spotlighting targeted immunotherapy and manageable early-cycle risks.